• Böhm
• Brčić
• Heinemann
• Höfler
Kargl ⏩
• Kwapiszewska
• Leithner
• Marsche
• Marsh
• Moissl-Eichinger
• Olschewski A
• Olschewski H
• Strobl
• Tomazic

Young Faculty




PhD Program
Congress (Retreat)


• Webmaster

The RESPImmun Faculty

Julia KARGL, PhD

The role of neutrophil-derived myeloperoxidase in non-small-cell lung cancer metastasis

Otto Loewi Research Centre, Division of Pharmacology, Medical University of Graz, Neue Stiftingtalstraße 6, A-8010 Graz;
phone: +43-316-385 74105, fax: +43-316-385 79613,  e-mail
websites: [RESPImmun]
• Profile     • Curriculum vitae     • PhD students     • Grants     • Publications ⏬    

List of publications:

10 most significant publications:

  1. Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, Maeda DY, Zebala JA, McKay-Fleisch J, Meredith G, Mashadi-Hossein A, Baik C, Pierce RH, Redman MW, Thompson JC, Albelda SM, Bolouri H, Houghton AM: Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight, 2019; 4(24):​e130850. (Highlighted at the NIH Director's Blog by Francis Collins)
  2. Lastwika KJ, Kargl J, Zhang Y, Zhu X, Lo E, Shelley D, Ladd JJ, Wu W, Kinahan P, Pipavath SNJ, Randolph TW, Shipley M, Lampe PD, Houghton AM: Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules. Am J Respir Crit Care Med, 2019; 199(10):​1257–1266.
  3. Mark NM, Kargl J, Busch SE, Yang GHY, Metz HE, Zhang H, Hubbard JJ, Pipavath SNJ, Madtes DK, Houghton AM: Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. Am J Respir Crit Care Med, 2018; 197(3):​325–336.
  4. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE Hubbard JJ, Lee SM, Madtes DK, McIntosh MW, Houghton AM: Neutrophils dominate the immune cell composition in non-small-cell lung cancer. Nat Commun, 2017; 8:14381.
  5. Metz HE, Kargl J, Busch SE, Kim KH, Kurland BF, Abberbock SR, Randolph-Habecker J, Knoblaugh SE, Kolls JK, White MF, Houghton AM: Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma. Proc Natl Acad Sci, 2016; 113(31):​8795–8800.
  6. Kargl J, Andersen L, Hasenöhrl C, Feuersinger D, Stancic A, Fauland A, Magnes C, El-Heliebi A, Lax S, Uranitsch S, Haybaeck J, Heinemann A, Schicho R: GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol, 2016; 173(1):​142–152.
  7. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, Heinemann A: A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther, 2013; 346(1):​54–66.
  8. Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M: The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem, 2012; 287(53):​44234–44248.
  9. Kargl J, Haybaeck J, Stančić A, Andersen L, Marsche G, Heinemann A, Schicho R: O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med (Berl), 2013; 91(4):​449–458.
  10. Kargl J, Balenga NA, Platzer W, Martini L, Whistler JL, Waldhoer M: The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55. Br J Pharmacol, 2012; 165(8):​2611–2619.